Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT04657003
|
| gptkbp:completedIn |
April 2022
|
| gptkbp:conditionStudied |
gptkb:type_2_diabetes
obesity overweight |
| gptkbp:designer |
double-blind
placebo-controlled randomized |
| gptkbp:foundIn |
tirzepatide led to significant weight loss in adults with obesity and type 2 diabetes
|
| gptkbp:fullName |
A Study of Tirzepatide in Participants With Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-2)
|
| https://www.w3.org/2000/01/rdf-schema#label |
SURMOUNT-2
|
| gptkbp:intervention |
gptkb:tirzepatide
|
| gptkbp:location |
multinational
|
| gptkbp:participants |
938
|
| gptkbp:period |
Phase 3
|
| gptkbp:publicationDate |
June 2023
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
percent change in body weight from baseline
|
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
December 2019
|
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|